Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.18−0.19 (-5.64%)
Close on Nov 16, 2026Market cap $222.90MP/E –Yield 0.00%
Bicycle Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Bicycle Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $175.25M, down 26.5% year over year. For fiscal 2025 it was $240.28M, up 38.9% from the year before. The highest annual figure on record is $240.28M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.28M | +38.9% |
| FY2024 | Dec 31, 2024 | $172.97M | +10.5% |
| FY2023 | Dec 31, 2023 | $156.50M | +91.8% |
| FY2022 | Dec 31, 2022 | $81.61M | +81.8% |
| FY2021 | Dec 31, 2021 | $44.88M | +35.4% |
| FY2020 | Dec 31, 2020 | $33.15M | +29.8% |
| FY2019 | Dec 31, 2019 | $25.54M | +23.0% |
| FY2018 | Dec 31, 2018 | $20.76M | +75.0% |
| FY2017 | Dec 31, 2017 | $11.87M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $33.42M | -42.8% |
| Q2 FY2026 | Jun 30, 2026 | $41.16M | -42.1% |
| Q1 FY2026 | Mar 31, 2026 | $48.90M | -17.2% |
| Q4 FY2025 | Dec 31, 2025 | $51.77M | +4.0% |
| Q3 FY2025 | Sep 30, 2025 | $58.43M | +21.1% |
| Q2 FY2025 | Jun 30, 2025 | $71.03M | +77.3% |
| Q1 FY2025 | Mar 31, 2025 | $59.06M | +69.4% |
| Q4 FY2024 | Dec 31, 2024 | $49.78M | +11.4% |
| Q3 FY2024 | Sep 30, 2024 | $48.27M | +21.1% |
| Q2 FY2024 | Jun 30, 2024 | $40.06M | +0.9% |
| Q1 FY2024 | Mar 31, 2024 | $34.86M | +8.2% |
| Q4 FY2023 | Dec 31, 2023 | $44.70M | +80.8% |
| Q3 FY2023 | Sep 30, 2023 | $39.87M | +75.2% |
| Q2 FY2023 | Jun 30, 2023 | $39.72M | +100.1% |
| Q1 FY2023 | Mar 31, 2023 | $32.21M | +125.5% |
| Q4 FY2022 | Dec 31, 2022 | $24.72M | +90.8% |
| Q3 FY2022 | Sep 30, 2022 | $22.75M | +116.4% |
| Q2 FY2022 | Jun 30, 2022 | $19.85M | +69.4% |
| Q1 FY2022 | Mar 31, 2022 | $14.28M | +47.4% |
| Q4 FY2021 | Dec 31, 2021 | $12.96M | +28.8% |
| Q3 FY2021 | Sep 30, 2021 | $10.51M | +42.8% |
| Q2 FY2021 | Jun 30, 2021 | $11.72M | +47.3% |
| Q1 FY2021 | Mar 31, 2021 | $9.69M | +24.7% |
| Q4 FY2020 | Dec 31, 2020 | $10.06M | +51.3% |
| Q3 FY2020 | Sep 30, 2020 | $7.36M | +21.1% |
| Q2 FY2020 | Jun 30, 2020 | $7.96M | +21.7% |
| Q1 FY2020 | Mar 31, 2020 | $7.77M | +23.9% |
| Q4 FY2019 | Dec 31, 2019 | $6.65M | +2.4% |
| Q3 FY2019 | Sep 30, 2019 | $6.08M | +7.7% |
| Q2 FY2019 | Jun 30, 2019 | $6.54M | +32.9% |
| Q1 FY2019 | Mar 31, 2019 | $6.28M | – |
| Q4 FY2018 | Dec 31, 2018 | $6.49M | – |
| Q3 FY2018 | Sep 30, 2018 | $5.64M | – |
| Q2 FY2018 | Jun 30, 2018 | $4.92M | – |
See a number that looks wrong?